Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Kaemmerer

Showing results (21-30 of 63) with videos related to

Pageof 7
Sort By:
International Journal of Clinical and Experimental Pathology|December 14, 2012
Correlation of monoclonal and polyclonal somatostatin receptor 5 antibodies in pancreatic neuroendocrine tumorsDaniel Kaemmerer, Amelie Lupp, Luisa Peter, et al.
Experimental and Molecular Pathology|May 24, 2024
Expression of free fatty acid receptor 2 in normal and neoplastic tissuesNiklas Ruhnke, Anna-Sophia Liselott Beyer, Daniel Kaemmerer, et al.
The Journal of Clinical Endocrinology and Metabolism|December 16, 2014
Somatostatin receptors in bronchopulmonary neuroendocrine neoplasms: new diagnostic, prognostic, and therapeutic markersDaniel Kaemmerer, Elisa Specht, Jörg Sänger, et al.
Oncotarget|June 4, 2016
Comparative evaluation of three proliferation markers, Ki-67, TOP2A, and RacGAP1, in bronchopulmonary neuroendocrine neoplasms: Issues and prospectsElisa Neubauer, Ralph M Wirtz, Daniel Kaemmerer, et al.
World Journal of Gastroenterology|December 10, 2009
Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumorDaniel Kaemmerer, Vikas Prasad, Wolfgang Daffner, et al.
Clinical & Experimental Metastasis|June 18, 2011
Localization of sporadic neuroendocrine tumors by gene expression analysis of their metastasesNicole Posorski, Daniel Kaemmerer, Guenther Ernst, et al.
Plos One|February 19, 2021
Immunohistochemical identification of complement peptide C5a receptor 1 (C5aR1) in non-neoplastic and neoplastic human tissuesBenjamin Nürge, Alan Lennart Schulz, Daniel Kaemmerer, et al.
BMC Cancer|July 7, 2022
Comparative evaluation of somatostatin and CXCR4 receptor expression in different types of thyroid carcinoma using well-characterised monoclonal antibodiesMax Czajkowski, Daniel Kaemmerer, Jörg Sänger, et al.
Oncotarget|August 11, 2015
Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancyDaniel Kaemmerer, Tina Träger, Maike Hoffmeister, et al.
Annals of Surgery|October 8, 2020
Prior Resection of the Primary Tumor Prolongs Survival After Peptide Receptor Radionuclide Therapy of Advanced Neuroendocrine NeoplasmsDaniel Kaemmerer, Matthias Twrznik, Harshad R Kulkarni, et al.
Pageof 7

Showing results (21-30 of 63) with videos related to

Sort By:
Pageof 7
International Journal of Clinical and Experimental Pathology|December 14, 2012
Correlation of monoclonal and polyclonal somatostatin receptor 5 antibodies in pancreatic neuroendocrine tumorsDaniel Kaemmerer, Amelie Lupp, Luisa Peter, et al.
Experimental and Molecular Pathology|May 24, 2024
Expression of free fatty acid receptor 2 in normal and neoplastic tissuesNiklas Ruhnke, Anna-Sophia Liselott Beyer, Daniel Kaemmerer, et al.
The Journal of Clinical Endocrinology and Metabolism|December 16, 2014
Somatostatin receptors in bronchopulmonary neuroendocrine neoplasms: new diagnostic, prognostic, and therapeutic markersDaniel Kaemmerer, Elisa Specht, Jörg Sänger, et al.
Oncotarget|June 4, 2016
Comparative evaluation of three proliferation markers, Ki-67, TOP2A, and RacGAP1, in bronchopulmonary neuroendocrine neoplasms: Issues and prospectsElisa Neubauer, Ralph M Wirtz, Daniel Kaemmerer, et al.
World Journal of Gastroenterology|December 10, 2009
Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumorDaniel Kaemmerer, Vikas Prasad, Wolfgang Daffner, et al.
Clinical & Experimental Metastasis|June 18, 2011
Localization of sporadic neuroendocrine tumors by gene expression analysis of their metastasesNicole Posorski, Daniel Kaemmerer, Guenther Ernst, et al.
Plos One|February 19, 2021
Immunohistochemical identification of complement peptide C5a receptor 1 (C5aR1) in non-neoplastic and neoplastic human tissuesBenjamin Nürge, Alan Lennart Schulz, Daniel Kaemmerer, et al.
BMC Cancer|July 7, 2022
Comparative evaluation of somatostatin and CXCR4 receptor expression in different types of thyroid carcinoma using well-characterised monoclonal antibodiesMax Czajkowski, Daniel Kaemmerer, Jörg Sänger, et al.
Oncotarget|August 11, 2015
Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancyDaniel Kaemmerer, Tina Träger, Maike Hoffmeister, et al.
Annals of Surgery|October 8, 2020
Prior Resection of the Primary Tumor Prolongs Survival After Peptide Receptor Radionuclide Therapy of Advanced Neuroendocrine NeoplasmsDaniel Kaemmerer, Matthias Twrznik, Harshad R Kulkarni, et al.
Pageof 7